Some thoughts on this Thursday before Good Friday.
Along with the volume and price increase, there has been a lot of chatter on the other board. Correspondingly, there has been an increase in the number of posts that have been removed, more by the ihub administrator than by moi. Most of these post removals derive from derisive posts of a single poster who seems to take great pleasure in promoting his theses and mocking those who disagree.
Separately, it is my opinion that Vitaros alone should support a buyout north of where we are, perhaps by multiples of the current price. That is bolstered by the brilliant buyback (imo) of the US rights by Pascoe. I still don't know how Pascoe did that. I also don't know how Vitaros will turn out in the long run. Right now it continues to be the turtle in the race to profitability with steady albeit slow sales increases, but with bumps in that road...Sandoz is the most recent example. The room temp device is another example that is still baffling to me. The most important upcoming development will be FDA consideration of Vitaros approval. Such approval will trigger a decision by Pfizer/Allergan on whether they want to keep Vitaros. I hope they do, but I would still be concerned that Pfizer will sit on Vitaros rather than aggressively commercialize it. Time will tell.
Regarding Fispemifine, that is very much a developing story. First, we should have Phase IIb results within the next few days. If the results are bad or ambiguous, that would be the end of the story. If the results look good, then what? Negotiation with FDA on Phase III design I suppose. And how much will that cost, how will that be funded, and how long will Phase III take?
Regarding RayVa, it moves to Phase IIb in the second half of this calendar year, but that puts it years away from marketability.
And what about the goals of big investors like Denner? They have moved to position of controlling the company by providing needed financing, and protecting themselves with warrants. Are they interested in growing the company or do they want a quick but good return on their investment through and orchestrated buyout?
This is not where I thought we would be when we were waiting for Canada approval of Vitaros. But I am still in for the ride. James |
